Moderna (MRNA) Common Equity (2017 - 2026)

Moderna (MRNA) has reported Common Equity for 10 consecutive years, with $6.8 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Common Equity fell 28.07% year-over-year to $6.8 billion in Q2 2026; TTM through Jun 2026 was $6.8 billion, a 28.07% decrease from a year earlier, with the FY2025 full-year figure at $8.6 billion, down 20.65% from the prior year.
• Common Equity was $6.8 billion for Q2 2026 at Moderna, down from $7.4 billion in the prior quarter.
• Over five years, Common Equity peaked at $19.1 billion in Q4 2022 and troughed at $6.8 billion in Q2 2026.
• A 5-year average of $13.0 billion and a median of $12.4 billion in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 344.89% in 2022 and tumbled 32.05% in 2024, its largest moves.
• Over 5 years, Common Equity stood at $19.1 billion in 2022, then decreased by 27.55% to $13.9 billion in 2023, then retreated by 21.32% to $10.9 billion in 2024, then slipped by 20.65% to $8.6 billion in 2025, then slipped by 21.84% to $6.8 billion in 2026.
• The last three Common Equity figures came in at $6.8 billion (Q2 2026), $7.4 billion (Q1 2026), and $8.6 billion (Q4 2025), per Business Quant data.